HCV / Hepatitis

The company detailed its preliminary 24-week post–end-of-treatment data for its tobevibart and elebsiran combination, which is being studied for chronic hepatitis B.

Anu Osinusi, MD provides insights on the findings of Gilead’s investigational therapy from its phase 3 MYR301 study, which are being reported at the ongoing European Association for the Study of the Liver (EASL) Congress 2025.

Anu Osinusi, MD, discusses the findings examining bulevirtide as a standalone therapy and in combination with pegylated interferon alpha.

LA County confirms 165 cases since 2024 with 29 in 2025 alone, including individuals without known risk factors.

Atea Pharmaceuticals' investigational combination treatment of bemnifosbuvir and ruzasvir showed these results after an 8-week treatment regimen.

Rising tick-borne illnesses due to warmer winters, strong hepatitis E vaccine efficacy during an outbreak, emerging fungal threats and resistance, and more.

The Hecolin hepatitis E virus vaccine was delivered with a reduced 2-dose schedule to people living in a refugee camp to try to reduce an outbreak.

World Malaria day stories, update on measles outbreak, coronavirus antivirals showing strong results in testing, and more this week.

Q&A with Ben Burwitz, PhD, on the significance of the new hepatitis B virus (HBV)-susceptible primate model and its potential to advance hepatitis B research and therapeutic development.

Atea Pharmaceuticals will present the full clinical study at the upcoming EASL Congress in May.

While 254 million affected globally with HBV, the disease remains endemic in Nigeria due to imperfect vaccination efficacy and limited coverage

Sarah Rowan, MD, on minimal laboratory testing, Hepatitis B screening flexibility, peer navigation, and state‑specific strategies to overcome outreach and reimbursement hurdles

Sarah Rowan, MD, says tailored models within syringe service programs can overcome barriers and improve cure rates in underserved populations.

Universal hepatitis C screening updates have influenced testing numbers, and resulted in a gradual increase for all women with a pronounced increase in pregnant women.

With valid phase 2 results, hydronidone could pave the way for first antifibrotic treatment in chronic liver disease.

Yael David, PhD, discusses how cccDNA nucleosome positioning drives HBV transcription and how CBL137 disrupts this process to block infection.

Precision BioSciences received the designation for its gene editing therapy, PBGENE-HBV, developed to eliminate the root cause of chronic hepatitis B virus (HBV).

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Although there have been decreases in newly reported chronic hepatitis C cases across many demographics, the need to get people screened and given therapy in the same visit remains vital.

Switching from tenofovir disoproxil fumarate to besifovir dipivoxil maleate improves renal and bone health without compromising antiviral efficacy.

This open-label trial will compare the combination of the company’s therapies, bemnifosbuvir and ruzasvir, with another hepatitis C combination regimen.

Long-term clinical and economic benefits of an inclusive national HCV program targeting mothers and infants, two often overlooked populations.

Development of a monoclonal antibody targeting mucormycosis, WHO’s call for improved fungal diagnostics and therapies, Bayesian dosing to optimize antimicrobial therapy, and more.

Andrew Aronsohn, MD, associate professor of Medicine, University of Chicago Medical Center, discusses the hepatitis C (HCV) screen and treat plan that looks to utilize a one visit approach to get people tested and on medication in the same patient encounter.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.